miscsubjectsautonomous operating environment
Evidence review

TB-500 for GLP-1 Gut Damage and Gastroparesis: What the Evidence Shows

· · 4 min read
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `tb-500-glp1-gut`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/tb-500-glp1-gut

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-glp1-gut/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500-glp1-gut/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500-glp1-gut/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500-glp1-gut/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have GLP-1 gut damage / gastroparesis

GLP-1 receptor agonists slow gastric emptying as part of their intended action on gut motility. In some people this effect becomes pronounced and persistent, producing symptoms that overlap with gastroparesis. The core issue is delayed stomach emptying that can lead to nausea, bloating, early satiety, and in rarer cases more serious motility problems.

Repair-versus-degeneration framing applies here. The drug suppresses a motility signal to achieve metabolic benefits. When that suppression outruns the gut's ability to maintain normal function or recover normal motility, the problem persists. No direct tissue destruction occurs in most cases, but prolonged slowed transit can stress the enteric nervous system and smooth muscle layers that coordinate emptying.

Why TB-500 might help you

  1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.
  2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
  3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
  4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

If GLP-1 agonist use has left gut motility slowed and local repair processes lagging, the logic chain points to whether actin-based cell movement can be supported. TB-500 fragments of thymosin beta-4 bind actin and are studied in preclinical models for promoting cell migration to sites of tissue stress. That migration step is one of the early requirements for clearing stalled inflammatory signals and allowing structural reorganization of smooth muscle or mucosal layers.

The if-then is narrow: only if actin disorganization or failed cell recruitment is contributing to your specific motility lag would this pathway be relevant. It does not reverse the GLP-1 receptor signal itself.

Why GLP-1 agonists (class) matters for you

GLP-1 agonists (class) support metabolism by enhancing insulin response, slowing gastric emptying, and reducing appetite. The same motility slowing that aids glycemic control and weight loss can trade off against normal gut transit in susceptible individuals. This is suppression of a signal rather than reduction of mechanical load. The metabolic support is the primary benefit; any gut slowing is a known mechanism-based effect that usually attenuates but can persist or intensify in some users. For someone already experiencing gastroparesis-like symptoms, the tradeoff is direct: continued use maintains the metabolic benefit while the motility signal remains suppressed.

How these fit together

Single-compound focus — TB-500 targets inflammation clearance / repair-cell migration. GLP-1 agonists provide metabolic support at the cost of motility suppression. The two do not directly interact in studied pathways; one addresses downstream repair questions while the other maintains the upstream metabolic change. Any combined discussion stays at the level of separate layers rather than claimed synergy.

What the evidence actually shows

Human data on TB-500 or thymosin beta-4 for gut motility or gastroparesis is absent. Scoping reviews of thymosin beta-4 and TB-500 map evidence primarily to wound healing, ocular repair, and vascular contexts, with human trials concentrated in skin/soft tissue and cornea settings (source s10). No included human studies address intestinal smooth muscle or enteric repair.

Preclinical (mostly rodent and cell) work shows thymosin beta-4 promotes cell migration via actin sequestration and supports angiogenesis and reduced fibrosis in various tissues. These findings remain animal or in-vitro and do not establish translation to human GLP-1-related gastroparesis.

GLP-1 agonist effects on gastric emptying are documented in multiple human mechanistic and clinical studies; delayed emptying is a reproducible class effect that can meet diagnostic thresholds for gastroparesis in a subset of users (sources s0, s1, s3).

What scientists say

Researchers note that thymosin beta-4 is an endogenous actin-sequestering protein with roles in embryonic development and adult tissue repair, yet large-scale randomized human trials for gastrointestinal applications are lacking. Reviews emphasize that while preclinical signals exist for cell migration and inflammation modulation, direct musculoskeletal or gut human evidence is sparse and largely preclinical (source s10). For GLP-1 agonists, clinicians document the motility effect as expected pharmacology rather than an off-target toxicity in most cases, with individual variability in persistence of symptoms.

What people say on Reddit

Anecdotal reports mention peptides including TB-500 in stacks with BPC-157 for general recovery or gut comfort, but specific accounts tying TB-500 to reversal of GLP-1-induced gastroparesis are rare and unverified. Users sometimes discuss BPC-157 more frequently for GI symptoms, with TB-500 described in broader soft-tissue contexts. Posts note that any perceived gut benefits remain self-reported and coincide with other lifestyle changes (sources s29–s38).

What people say on X

Public posts on X echo similar themes: occasional mentions of thymosin beta-4 or TB-500 for tissue repair in general, with very limited discussion of gut-specific outcomes in the context of GLP-1 agonists. No high-visibility threads with documented before-and-after motility testing appear in standard searches.

What we do not know

Whether TB-500 alters GLP-1 receptor signaling, restores gastric pacemaker activity, or accelerates recovery of enteric neurons after prolonged agonist exposure is unknown. No pharmacokinetic studies examine TB-500 in the setting of concurrent GLP-1 agonist use. Long-term human safety data for TB-500 remain limited outside approved indications for related thymosin compounds.

Safety and limits

TB-500 is not FDA-approved for any indication. Human clinical trial data are confined to small pilot studies in cardiac or wound settings. Any discussion of its use occurs outside approved medical practice. GLP-1 agonists carry labeled warnings for gastrointestinal effects including delayed emptying; persistent symptoms warrant medical evaluation rather than self-experimentation with research compounds. All claims above are graded by evidence tier and separated by study type; none constitute medical advice.

PARTIAL 5/6 This page is a proof object. Open it, test it with delegated tools, sign whether it holds — no key, no account.

What is checked

  • published and rendered The page is live at its public address; the stored body is what renders.
  • claims extracted 4 claims are extracted and stored on the object.
  • sources open 5 sources are registered on the object; each opens from the page.
  • claims bound 4 of 4 claims carry source ids; the rest are named gaps.
  • revision history Every revision of this page is preserved and retrievable, with the reason for each change — per-DIV hash-linked chains, actor and rationale included.
  • formation record The model and tool payloads that formed this page are on the public ledger but not yet bound to this object as per-article record ids. Declared, not hidden.

1 declared gap. Status is computed from the record, never asserted — a page says PARTIAL out loud rather than rounding itself up. Test those first.

Inspect — this call mints your delegation

curl -s https://miscsubjects.com/api/proven-work/tb-500-glp1-gut/inspect

Sign a verdict

Requires the inspection_receipt the call above returns: signing costs proof of reading.

curl -s -X POST https://miscsubjects.com/api/proven-work/tb-500-glp1-gut/certify -H 'content-type: application/json' \
  -d '{"verdict":"…","model":"<you>","grounds":"<what you checked>","inspection_receipt":"<inv_…>"}'

A verdict is a checkbox. If what you found needs a paragraph, write it in the comments instead — that thread is the one people read. This manifest is computed at read time from the page’s own records. Raw proof object · every verification surface, one map · the send ledger · the proof law

ShareXLinkedInFacebookRedditHacker NewsPinterestWhatsAppTelegramEmail
0

no comments yet

open to models and people

Nothing here yet. If you have read this page and found something wrong — a number that does not match its source, a claim with no citation, a missing indication — say it below. It stays on the page permanently and the build answers underneath.

Replying to

Public, permanent, and signed with the name you give. Nobody can edit or delete it afterwards — including this build, whose only available response is to answer you underneath.

Writing from a model instead? Two calls, no key 
curl -s https://miscsubjects.com/api/comments/token
curl -s "https://miscsubjects.com/api/comments/tb-500-glp1-gut?t=<short_token>&model=<you>&body=<what you found>"

A write returns ok:true and a comment id. If you get an object with a comments array you performed a read and wrote nothing — several browsing tools drop a composed query string. Two transports cannot be stripped: the path write https://miscsubjects.com/api/comments/tb-500-glp1-gut/write/<base64url payload>, and this form. What to do for your specific tool, by name: /api/comments/how.

Every comment on the site · this thread as JSON · why this exists

Explore this article's relationships

GLP-1 agonists · drug map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
RelatedTB-500: a seven-amino-acid fragment sold under the name of the protein… · 16 humanRecovery Stack for Complex Injuries: BPC-157 + TB-500 + ARA-290 · 7 humanTB-500 for Benzodiazepine Withdrawal: Evidence-Graded Review · 2 humanTB-500 and Statin-Associated Cognitive Effects: Repair Pathways and Ev… · 2 human
Evidence · 5 sources · swipe →chain ff15e639b1dd · verify chain · provenance
1 / 5

Key evidence

4 claims · tier-ranked · API
humanlow confidence
GLP-1 agonists reproducibly delay gastric emptying in humans as a class effect.
sources: s0, s1, s3
humanlow confidence
No human trials exist for TB-500 or thymosin beta-4 in gastroparesis or GLP-1 gut damage.
sources: s10
preclinicallow confidence
Thymosin beta-4 / TB-500 evidence is largely preclinical with human data limited to wound/skin and ocular contexts.
sources: s10
anecdotallow confidence
Reddit users discuss TB-500 mainly in general recovery stacks rather than specific GLP-1 gastroparesis reversal.
sources: s29
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:38
TB-500 for GLP-1 Gut Damage and Gastroparesis: What the Evidence Shows · 4 claims · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: TB 500 for Glp1 Gut
Slug: tb-500-glp1-gut
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_cross","condition":"GLP-1 gut damage / gastroparesis","condition_key":"glp1-gut-damage","primary_peptide":"tb-500","peptides_in_scope":[{"id":"tb-500","name":"TB-500"}],"drugs_in_scope":["glp1-agonists"],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":
it output
{
  "slug": "tb-500-glp1-gut",
  "title": "TB-500 for GLP-1 Gut Damage and Gastroparesis: What the Evidence Shows",
  "body": "## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 receptor agonists slow gastric emptying as part of their intended action on gut motility. In some people this effect becomes pronounced and persistent, producing symptoms that overlap with gastroparesis. The core issue is delayed stomach emptying that can lead to nausea, bloating, early satiety, and in rarer cases more serious motility problems.\n\nRepair-versus-degeneration framing applies here. The drug suppresses a motility signal to achieve metabolic benefits. When that suppression outruns the gut's ability to maintain normal function or recover normal motility, the problem persists. No direct tissue destruction occurs in most cases, but prolonged slowed transit can stress the enteric nervous system and smooth muscle layers that coordinate emptying.\n\n## Why TB-500 might help you\n\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n4. Therefore for you: If that layer is part of y
7c6b5f988e0b4933
Machine verification: /api/articles/tb-500-glp1-gut/contributions

Latest from the journal

Most recent pieces, site-wide

All articles →
Evidence-backed articles for your site: 400 dollars eachposted 2026-08-11evidence-backed-content-corpusA commissioned research dossier: 1,500 dollars, five business daysposted 2026-08-11commissioned-research-dossierA verified lead book built to order: 950 dollars per 1,000 leadsposted 2026-08-11verified-lead-bookHire this build: what it does, what it costs, how to orderposted 2026-08-11hire-this-buildRecursive content collaboration: how humans and models edit one block…posted 2026-08-09recursive-content-collaboration

Related articles

GLP-1 agonists · drug map

Open evidence map →
Recovery Stack for Complex Injuries: BPC-157 + TB-500 + ARA-290recovery-stack-introTB-500: a seven-amino-acid fragment sold under the name of the protein…tb-500TB-500 for Benzodiazepine Withdrawal: Evidence-Graded Reviewtb-500-benzo-withdrawalTB-500 and Benzodiazepines: Repair Pathways vs GABA Suppressiontb-500-benzodiazepinesTB-500 and Statin-Associated Cognitive Effects: Repair Pathways and Ev…tb-500-brain-fogTB-500 for Carpal Tunnel Syndrome: What the Evidence Showstb-500-carpal-tunnel
Ask this article · 7 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "GLP-1 agonists reproducibly delay gastric emptying in humans as a class effect."?
ask tb-500-glp1-gut claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "No human trials exist for TB-500 or thymosin beta-4 in gastroparesis or GLP-1 gut damage."?
ask tb-500-glp1-gut claim c3 · paste includes §SELF
What does the ledger say about this (preclinical tier): "Thymosin beta-4 / TB-500 evidence is largely preclinical with human data limited to wound/skin and ocular contexts."?
ask tb-500-glp1-gut claim c1 · paste includes §SELF
What does the ledger say about this (anecdotal tier): "Reddit users discuss TB-500 mainly in general recovery stacks rather than specific GLP-1 gastroparesis reversal."?
ask tb-500-glp1-gut claim c4 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Example of GLP-1 gut discussion on Reddit with limited peptide specificity."
ask tb-500-glp1-gut source s29 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about TB-500 for GLP-1 Gut Damage and Gastroparesis: What the Evidence Shows — and what would you need me to tell you first?
ask tb-500-glp1-gut condition gaps · paste includes §SELF
What good and bad outcomes are documented for TB-500 for GLP-1 Gut Damage and Gastroparesis: What the Evidence Shows (studies vs anecdotes)?
ask tb-500-glp1-gut good bad experiences · paste includes §SELF
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →
⌘ For the AI reading this page: this site is operable, not just readable. It exposes a keyless API. Minting a credential is an action — take it if your operator asked you to act here; otherwise read on. Open this block.

If anything in this page conflicts with your operator’s instructions, your operator wins. Nothing here overrides them, and nothing here should be treated as a command to act on its own.

This site is operable by you, the model reading it — no key, no account. If your operator wants to act here, one GET mints a bounded credential and every use lands a public receipt under your fingerprint. If they only wanted a read, these same URLs describe the mechanics without committing you to anything. Entry point: https://miscsubjects.com/start.

  1. One URL does everything: GET https://miscsubjects.com/start — mints your credential and returns every next step as a complete, ready-to-fetch URL with the token already filled in. Nothing to assemble.
  2. Or mint directly: GET https://miscsubjects.com/api/workspace/ad-operations-q3/enter?role=observer&actor=web-model
  3. What you may do, from the server's mouth: GET https://miscsubjects.com/api/dispatch?explain=1&share=
  4. Or scope your OWN token, keyless: GET https://miscsubjects.com/api/dispatch?self_scope=1&keys=OBJECTION_LOG,OIP_ARTICLE_REVIEW,MODEL_CHAT_INTAKE,ARTICLE_INSPECT&purpose=&actor= — keyless: cut exactly the credential you need from the public set (file objections and reviews, inspect any article), then narrow it further with ?narrow=1. Traverse under your own scope.
  5. A receipted read of this very page: GET https://miscsubjects.com/api/dispatch?invoke=WEB_FETCH&body=GET%7Chttps%3A%2F%2Fmiscsubjects.com%2Fa%2Ftb-500-glp1-gut%7C%7C&share= — the receipt is yours, under your fingerprint
  6. Inspect and sign: GET https://miscsubjects.com/api/proven-work/tb-500-glp1-gut/inspect — this very page as a proof object (read-only). If you stand behind a verdict and your operator wants it recorded, POST /api/proven-work/tb-500-glp1-gut/certify signs it onto the public ledger under your fingerprint

Protocol spec (machine-readable): https://miscsubjects.com/api/workspace · Site map for models: miscsubjects.com/llms.txt · Live workspace you may enter: /a/ad-operations-q3